Muscle founder cells are uniquely speci®ed cells that fuse with neighboring myoblasts to generate the complex pattern of body wall muscles in the Drosophila embryo. We have investigated the positional speci®cation of founder cells for ventral oblique muscles, marked by the restricted expression of tinman RNA and the activity of a D-mef2 enhancer. The formation of these ventral myoblasts requires the function of the Heartless FGF receptor in the mesoderm and the presence of ventral neuroblasts in the central nervous system. Overproduction of ventral neuroblasts due to the forced expression of the homeodomain protein Vnd leads to increased numbers of founder cells. These results suggest the use of a neuroectoderm-to-mesoderm signaling pathway in the speci®cation of ventral muscle precursors.
Muscle founder cells are uniquely speci®ed cells that fuse with neighboring myoblasts to generate the complex pattern of body wall muscles in the Drosophila embryo. We have investigated the positional speci®cation of founder cells for ventral oblique muscles, marked by the restricted expression of tinman RNA and the activity of a D-mef2 enhancer. The formation of these ventral myoblasts requires the function of the Heartless FGF receptor in the mesoderm and the presence of ventral neuroblasts in the central nervous system. Overproduction of ventral neuroblasts due to the forced expression of the homeodomain protein Vnd leads to increased numbers of founder cells. These results suggest the use of a neuroectoderm-to-mesoderm signaling pathway in the speci®cation of ventral muscle precursors.
Keywords: D-mef2; heartless; muscle founder cells; signal transduction; ventral neuroblasts During Drosophila embryogenesis, an elaborate pattern of body wall muscles is produced which allows for the subsequent motility and feeding of the hatched larva. About 30 muscles are formed in each thoracic hemisegment and these syncytial ®bers possess distinct characteristics in terms of their size, shape, location, and innervation (Bate, 1993) . This complex array is produced through the fusion of a founder cell for each muscle with neighboring fusion-competent myoblasts (Rushton et al., 1995) . The founder cells constitute a specialized group of myoblasts that are uniquely speci®ed based on the intercellular signals they receive and the mesodermal regulators they express (Baylies et al., 1998) .
Dierent signaling pathways are known to function in founder cell speci®cation. In the absence of wingless (wg) gene activity, speci®c subsets of muscle precursors fail to form (Volk and VijayRaghavan, 1994; Baylies et al., 1995; Ranganayakulu et al., 1996; Gajewski et al., 1998; Nguyen and Xu, 1998) . Similar results are obtained in embryos with mutations in genes encoding the epidermal growth factor receptor DER and its secreted ligand Spitz (Spi; Bu et al., 1998) . About half of the body wall muscles are missing in mutant embryos and the absence of many of these ®bers can be traced back to a failure to segregate the corresponding founder myoblasts. The Heartless (Htl) ®broblast growth factor (FGF) receptor, known to function early in embryogenesis in the directional migration of the mesoderm (Beiman et al., 1996; Gisselbrecht et al., 1996; Shishido et al., 1997) , is also required later for the speci®cation of muscle precursors in the somatic mesoderm . Therefore, several inductive processes have been implicated in the formation of embryonic muscle precursors. Information has emerged on the overlying ectoderm as an extrinsic source of inductive signals used to specify founder cells within the adjacent mesoderm (Lewis and Crews, 1994; Baker and Schubiger, 1995; Bate and Baylies, 1996) . Such secreted factors could include Wg, Spi, and the unidenti®ed ligand for the Htl receptor.
During the course of our studies on the function of the myogenic factor D-MEF2, we characterized a transcriptional enhancer with activity in the founder cells of ventral oblique muscles (Lewis and Crews, 1994; Gajewski et al., 1997 Gajewski et al., , 1998 . One known regulator of this enhancer is the homeodomain protein Tinman (Tin), demonstrating a function for Tin in both dorsal (Azpiazu and Frasch, 1993; Bodmer, 1993) and ventral mesodermal domains during myogenesis. Concerning its role in the ventral mesoderm, both Tin binding sites and tin function are required for enhancer activity in the founder cells. To demonstrate tin expression in these ventral cells around the time of their speci®cation and the activation of the D-mef2 enhancer, we monitored RNA accumulation in embryos by in situ hybridization. In late stage ten embryos, a high level of tin RNA is detected in the dorsal mesoderm ( Figure 1a ) at a time when gene expression is under the inductive in¯uence of Dpp produced by the dorsal ectoderm (Frasch, 1995; . At the same stage, tin RNA is also detected at a low level in 11 pairs of segmentally-repeated cells in the ventral mesoderm (Figure 1b) . Based on double stainings, these cells correspond to the founder cells that express the D-mef2 enhancer-lacZ fusion gene. In stage 11 embryos, transcripts are detected in the dierentiating dorsal mesoderm in precursors of the heart and visceral muscle lineages (Figure 1c ). In contrast, there is an absence of tin RNA in the ventral mesoderm at this later stage (Figure 1d ). This analysis reveals a novel, transient pattern of tin gene expression in ventral muscle founder cells. Such expression is consistent with the requirement of tin in the regulation of the D-mef2 founder cell enhancer.
The expression of an activated form of Ras1 throughout the mesoderm results in an overproduction of ventral founder cells (Gajewski et al., 1998) .
This observation suggested the involvement of a receptor tyrosine kinase signaling pathway in the speci®cation of these cells. Two such receptors are known to function in the Drosophila mesoderm: DER and Htl (Beiman et al., 1996; Gisselbrecht et al., 1996; Shishido et al., 1997; Michelson et al., 1998) . To determine if the function of either of these genes was required for the speci®cation of the ventral founder cells, we used the Gal4/UAS system (Brand and Perrimon, 1993) to express dominant negative forms of the receptors throughout the mesoderm under the control of a twiGal4 driver. In this analysis, the expression of both tin and the D-mef2 enhancer were used to monitor ventral cell formation. In embryos expressing a dominant negative form of DER (Figure 2c,d ), ventral muscle founder cells are speci®ed, but the level of expression of both markers is somewhat reduced relative to wild type embryos (Figure 2a, b) . In contrast, we failed to detect any tin or lacZ gene expression in embryos expressing a dominant negative form of Htl (Figure 2e,f) . Likewise, the majority of the muscle precursors failed to form in htl loss-offunction embryos (Figure 3b ). These results demon- The twi-Gal4 strain has been described in Baylies and Bate (1996) . The UAS lines used were UAS-DNDER [62; II and III] and UAS-DNhtl [62; II and III] . The Dmef2 enhancer-lacZ reporter strain used was IIA341 (Gajewski et al., 1998) . Processing and immunostaining of whole-mount embryos for b-galactosidase activity was as described in Gajewski et al. (1998) strate an essential role of the Htl receptor in the speci®cation of the ventral muscle founder cells.
Ras1 acts downstream of Htl in the signal transduction pathway controlling mesodermal cell migration and pericardial cell fate speci®cation (Gisselbrecht et al., 1996; Michelson et al., 1998) . To determine if this epistatic relationship also existed in ventral founder cell speci®cation, we monitored the formation of the muscle precursors in embryos expressing the dominant negative form of Htl and the activated form of Ras1. As noted, there is an absence of founder cells in embryos expressing the altered form , (c) twi-Gal4;UAS-Ras1
Act , and (d) twi-Gal4;UAS-Ras1 Act ;UAS-DNhtl embryos. While no founder cells are formed in embryos expressing DNhtl, and supernumerary founder cells are seen with the expression of activated Ras1, an intermediate number of founder cells is detected when the two proteins are co-expressed in the mesoderm. Methods: Dmef2 enhancer-lacZ expression was monitored in embryos with mesodermal expression of the activated Ras1 protein as described in Gajewski et al. (1998) . To analyse enhancer function in embryos expressing both the activated Ras1 protein and the dominant negative form of Htl, twi-Gal4;IIA341 D-mef2-lacZ females were crossed with UAS-Ras1
Act /UAS-DNhtl;+/UAS-DNhtl males. To analyse the expression of the D-mef2-lacZ fusion gene in the htl loss-of-function mutant background, IIA515 animals (Gajewski et al., 1998) were crossed to htl AB42 /TM3,ftz-lacZ¯ies (Gisselbrecht et al., 1996) . Progeny lacking the balancer chromosome were collected and mated, followed by scoring embryos for expression phenotypes (Jimenez and Campos-Ortega, 1990 )¯ies, respectively. Progeny lacking the balancer chromosomes were collected and mated, followed by scoring embryos for expression phenotypes. The pattern of D-MEF2 protein accumulation was analysed in embryos obtained from the cross of vnd 6 /FM7 females and FM7/Y males. Anti-D-MEF2 polyclonal antibody (Lilly et al., 1995) was used at a dilution of 1 : 1000 and a goat anti-rabbit-biotin conjugated secondary antibody (Vector, Burlingham, CA, USA) was used at the same dilution. The D-MEF2 pattern was visualized using the Vectastain Elite ABC Kit (Vector) of Htl (Figure 2e,f) while there is an overproduction of these cells in embryos expressing the modi®ed form of Ras1 (Figure 3c ; Gajewski et al., 1998) . When both are present in the mesoderm (Figure 3d ), an intermediate phenotype is observed where several D-mef2 enhancerlacZ expressing cell clusters are formed in an abnormal pattern relative to wild type ( Figure 3a ) and in numbers intermediate to those produced in dominant negative Htl and activated Ras1 expressing embryos. This partial rescue of the ventral cells is consistent with Ras1 acting downstream of Htl in ventral founder cell speci®cation.
Since a normal ventral identity of ectodermal cells is required for the production of the ventral muscle precursors, we assayed for founder cell speci®cation in embryos that fail to form subsets of cells in the adjacent central nervous system (CNS). In ventral nervous system defective (vnd) embryos, ventral neuroblasts fail to form and cells that are present in their position instead develop intermediate neuroblastlike fates (Chu et al., 1998; McDonald et al., 1998) . Ventral founder cells are not speci®ed in this genetic background as shown by the absence of D-mef2 enhancer-lacZ expression (Figure 4b ). In single-minded (sim) embryos, midline cells of the nervous system fail to dierentiate properly and ventral neuroblast-like cells become located along the embryonic midline (Nambu et al., 1990) . In these mutants, founder cell speci®cation does occur, but the cells are present in 11 segmentally-repeated groups that are clustered along the midline (Figure 4c) . From these experiments, we conclude that the presence and proper location of the ventral neuroblasts is vital to the correct speci®cation and positioning of the ventral muscle founder cells. This could occur through the production of a signal by the neuroblasts that is received by the Htl receptor, initiating the speci®cation process in select mesodermal cells.
With the absence of speci®c muscle founder cells in vnd mutants, a corresponding de®ciency of ventral muscles would be anticipated in the embryos. To test this prediction, we stained wild type and mutant embryos for D-MEF2 protein that is present in the nuclei of all body wall muscles (Figure 4d,e) . This analysis revealed reproducible muscle deletions in ventral regions of the vnd embryos. While the ventral acute, most ventral longitudinal, and ventral transverse muscles are usually present, the embryos fail to form the ventral oblique and ventral longitudinal 4 muscles. Thus, the ventral neuroblasts have an indispensable role in the genesis of several ventrally-located body wall muscles.
Since these results demonstrated a requirement for ventral neuroblasts in founder cell speci®cation and muscle formation, it was of interest to assess the precursors in embryos with an excess number of ventral neuroblasts. It has been shown that ectopic expression of the neuroblast identity gene vnd induces ventral fates at the expense of intermediate and dorsal fates within the CNS (Chu et al., 1998; McDonald et al., 1998) . Using the ectodermal Gal4 driver 69B and a UAS-vnd fusion gene, the Vnd homeodomain protein was expressed throughout the ectoderm and the production of ventral neuroblasts and founder cells was determined. Under these conditions, extra ventral neuroblasts are present based on the staining for Evenskipped (Eve) protein which marks select progeny of these cells (Figure 5b) . Likewise, supernumerary founder cells were observed in these embryos based on the expression of the D-mef2 enhancer-lacZ gene (Figure 5d ). In contrast, the number of muscle founders did not increase when Vnd was expressed throughout the mesoderm (data not shown). These results further support the belief that cells of the neuroectoderm play a prominent role in the patterning of the mesoderm.
A model of the genetic inputs used in the speci®cation of the ventral muscle founder cells is given in Figure 6 . We hypothesize that an inductive molecule is produced by Vnd-expressing ventral Figure 5 Overproduction of ventral neuroblasts results in increased numbers of ventral muscle founder cells. Eve protein was used as a marker for derivatives of ventral neuroblasts in (a) wild type and (b) 69B-Gal4;UAS-vnd 21 embryos. The D-mef2 founder cell enhancer-lacZ fusion gene was used as a marker for ventral muscle precursors in (c) wild type and (d) 69B-Gal4; UAS-vnd 21 embryos. Arrows point to the extra neural or myoblast cells. Methods: The ectodermal Gal4 driver strain used was 69B (Brand and Perrimon, 1993) and the UAS-vnd 21 line has been described previously (Chu et al., 1998) . A monoclonal antibody against the Eve protein (Developmental Studies Hybridoma Bank, University of Iowa, IA, USA) was used at a dilution of 1 : 150 and a horse antimouse-biotin conjugated secondary antibody (Vector) was used at a dilution of 3 : 1000. The Eve pattern was visualized using the Vectastain Elite ABC Kit neuroblasts of the developing CNS. This extrinsic in¯uence is received by the Htl receptor tyrosine kinase on the surface of select ventral mesodermal cells, leading to the induction of signal transduction events that involve the Ras1 protein. Tin and its unidenti®ed co-factor (Gajewski et al., 1998) would then activate D-mef2 expression within the nucleus. It remains to be determined whether Tin, or its partner, are regulated by similar signaling events. Wg also plays a role (albeit unknown) in this speci®cation process. Thus, the combined activities of the Htl and Wg signaling pathways are essential for the unique speci®cation of the founder cells from among the mesodermal cell population.
The nature of the signal produced by the ventral neuroblasts is unclear. The factor could be secreted or remain membrane-associated in the neural cells. A single FGF gene called branchless (bnl) has been identi®ed in Drosophila (Sutherland et al., 1996) . Bnl serves as the ligand for Breathless, an FGF receptor that functions in the development of the tracheal system (Reichman-Fried et al., 1994; Reichman-Fried and Shilo, 1995) . However, Bnl is unlikely to be the ligand for Htl in ventral founder cell speci®cation as it is not expressed in ventral neuroblasts and a mesodermal phenotype has not been observed in bnl mutant embryos. Therefore, additional investigations will be required to identify and characterize the Htl ligand.
It is evident that Htl function is required for founder cell speci®cation as mesodermal expression of a dominant negative version of the protein results in a lack of the ventral muscle precursors, and most of these cells are likewise missing in htl mutant embryos. Why some of the cells persist in the htl null background is unclear, but their formation may reflect a maternal contribution of the gene. Several other markers used in the analysis of the htl phenotype showed diminished, but not abolished, expression in mutant embryos (Gisselbrecht et al., 1996) . Thus, it is conceivable that the dominant inhibitory receptor may be preventing the function of both maternal and zygotic Htl protein. In contrast, it appears that signaling through DER is not absolutely required for the speci®cation of these founder cells based on the presence of the muscle precursors in embryos expressing a dominant negative form of the receptor and embryos mutant for the ligand Spi (K Gajewski and RA Schulz, unpublished observations). However, DER may play a quantitative role in this process as the levels of both tin and D-mef2-lacZ expression are reduced in embryos expressing the dominant negative receptor.
In conclusion, our results contribute to the expanding evidence for the conservation of genes controlling myogenesis in Drosophila and higher eukaryotes. In¯ies, the mesodermal segment appears to be patterned by an inductive signal from the neuroectoderm through the Htl pathway to specify distinct muscle founder cells. Similarly, signaling through an FGF receptor may be instrumental in the patterning of the vertebrate somite as myf-5 mutant mice fail to express FGF4 and FGF6 in their myotomes and undergo abnormal rib chondrocyte development (Grass et al., 1996) . Future studies on founder cell speci®cation should provide bene®cial insights into these conserved myogenic processes. Figure 6 Proposed model of a genetic pathway used in the speci®cation of ventral muscle founder cells. Circles indicate a secreted factor produced by the Vnd-expressing ventral neuroblasts; current results do not exclude the presence of a membraneassociated signaling molecule. The inductive signal would function through the Htl RTK-Ras1 pathway to specify ventral somatic muscle founder cells in the mesoderm. The triangle represents a putative co-activator protein that works with the Tin myogenic factor to activate D-mef2 expression in the founder cells. The Wg secreted factor also has an essential function in the speci®cation of these cells
